Which has preferable valuation and earnings, ASRT or SCYX?

SCYNEXIS has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Assertio $118.71M 1.28 -$30.38M -$5.69 N/A SCYNEXIS $20.60M 2.01 -$8.61M -$3.84 N/A

Is ASRT or SCYX more profitable?

Assertio has a net margin of -34.94% compared to SCYNEXIS's net margin of -41.79%. Assertio's return on equity of -38.72% beat SCYNEXIS's return on equity. Company Net Margins Return on Equity Return on Assets Assertio -34.94% -38.72% -13.32% SCYNEXIS -41.79% -57.16% -39.48%

Does the media favor ASRT or SCYX?

In the previous week, SCYNEXIS had 2 more articles in the media than Assertio. MarketBeat recorded 6 mentions for SCYNEXIS and 4 mentions for Assertio. Assertio's average media sentiment score of 0.77 equaled SCYNEXIS'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SCYX or SPRB?

In the previous week, SCYNEXIS had 4 more articles in the media than Spruce Biosciences. MarketBeat recorded 6 mentions for SCYNEXIS and 2 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.94 beat SCYNEXIS's score of 0.77 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SCYX or TLSA?

SCYNEXIS presently has a consensus target price of $24.00, suggesting a potential upside of 476.09%. Given SCYNEXIS's stronger consensus rating and higher probable upside, equities analysts plainly believe SCYNEXIS is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, SCYX or TLSA?

SCYNEXIS has higher revenue and earnings than Tiziana Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SCYNEXIS $20.60M 2.01 -$8.61M -$3.84 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media favor SCYX or TLSA?

In the previous week, SCYNEXIS had 3 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 6 mentions for SCYNEXIS and 3 mentions for Tiziana Life Sciences. SCYNEXIS's average media sentiment score of 0.77 beat Tiziana Life Sciences' score of 0.63 indicating that SCYNEXIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SCYX or ADCT more profitable?

SCYNEXIS has a net margin of -41.79% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat SCYNEXIS's return on equity. Company Net Margins Return on Equity Return on Assets SCYNEXIS -41.79% -57.16% -39.48% ADC Therapeutics -173.02% N/A -44.70%

Does the media favor SCYX or ADCT?

In the previous week, ADC Therapeutics had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 7 mentions for ADC Therapeutics and 6 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.77 beat ADC Therapeutics' score of 0.10 indicating that SCYNEXIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CGTX or SCYX?

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 6 articles in the media. Cognition Therapeutics' average media sentiment score of 0.78 beat SCYNEXIS's score of 0.77 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SCYNEXIS (SCYX) Competitors

$4.07 +0.20 (+5.04%)

As of 12:40 PM Eastern

Compare

SCYX vs. ASRT, SPRB, TLSA, ADCT, and CGTX

Should you buy SCYNEXIS stock or one of its competitors? MarketBeat compares SCYNEXIS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SCYNEXIS include Assertio (ASRT), Spruce Biosciences (SPRB), Tiziana Life Sciences (TLSA), ADC Therapeutics (ADCT), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.

How does SCYNEXIS compare to Assertio?

Assertio (NASDAQ:ASRT) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Assertio presently has a consensus price target of $22.65, suggesting a potential downside of 3.62%. SCYNEXIS has a consensus price target of $24.00, suggesting a potential upside of 476.09%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

49.0% of Assertio shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 5.7% of Assertio shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, SCYNEXIS had 2 more articles in the media than Assertio. MarketBeat recorded 6 mentions for SCYNEXIS and 4 mentions for Assertio. Assertio's average media sentiment score of 0.77 equaled SCYNEXIS'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assertio has a net margin of -34.94% compared to SCYNEXIS's net margin of -41.79%. Assertio's return on equity of -38.72% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
SCYNEXIS	-41.79%	-57.16%	-39.48%

SCYNEXIS has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
SCYNEXIS	$20.60M	2.01	-$8.61M	-$3.84	N/A

Assertio has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Summary

SCYNEXIS beats Assertio on 10 of the 15 factors compared between the two stocks.

How does SCYNEXIS compare to Spruce Biosciences?

SCYNEXIS (NASDAQ:SCYX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

SCYNEXIS has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.12, meaning that its stock price is 212% more volatile than the broader market.

In the previous week, SCYNEXIS had 4 more articles in the media than Spruce Biosciences. MarketBeat recorded 6 mentions for SCYNEXIS and 2 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.94 beat SCYNEXIS's score of 0.77 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spruce Biosciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Spruce Biosciences	N/A	-155.40%	-101.67%

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

SCYNEXIS currently has a consensus target price of $24.00, indicating a potential upside of 476.09%. Spruce Biosciences has a consensus target price of $163.00, indicating a potential upside of 191.62%. Given SCYNEXIS's higher probable upside, research analysts clearly believe SCYNEXIS is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

SCYNEXIS has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.01	-$8.61M	-$3.84	N/A
Spruce Biosciences	$4.91M	31.31	-$38.97M	-$36.60	N/A

Summary

SCYNEXIS and Spruce Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to Tiziana Life Sciences?

SCYNEXIS (NASDAQ:SCYX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Tiziana Life Sciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Tiziana Life Sciences' return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Tiziana Life Sciences	N/A	N/A	N/A

54.4% of SCYNEXIS shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SCYNEXIS has higher revenue and earnings than Tiziana Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.01	-$8.61M	-$3.84	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

In the previous week, SCYNEXIS had 3 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 6 mentions for SCYNEXIS and 3 mentions for Tiziana Life Sciences. SCYNEXIS's average media sentiment score of 0.77 beat Tiziana Life Sciences' score of 0.63 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SCYNEXIS presently has a consensus target price of $24.00, suggesting a potential upside of 476.09%. Given SCYNEXIS's stronger consensus rating and higher probable upside, equities analysts plainly believe SCYNEXIS is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SCYNEXIS has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Summary

SCYNEXIS beats Tiziana Life Sciences on 9 of the 13 factors compared between the two stocks.

How does SCYNEXIS compare to ADC Therapeutics?

SCYNEXIS (NASDAQ:SCYX) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

SCYNEXIS currently has a consensus price target of $24.00, indicating a potential upside of 476.09%. ADC Therapeutics has a consensus price target of $6.25, indicating a potential upside of 503.86%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ADC Therapeutics had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 7 mentions for ADC Therapeutics and 6 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.77 beat ADC Therapeutics' score of 0.10 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

SCYNEXIS has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

SCYNEXIS has a net margin of -41.79% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
ADC Therapeutics	-173.02%	N/A	-44.70%

SCYNEXIS has higher earnings, but lower revenue than ADC Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.01	-$8.61M	-$3.84	N/A
ADC Therapeutics	$79.18M	1.66	-$142.62M	-$1.05	N/A

Summary

ADC Therapeutics beats SCYNEXIS on 10 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 6 articles in the media. Cognition Therapeutics' average media sentiment score of 0.78 beat SCYNEXIS's score of 0.77 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cognition Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Cognition Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 196.30%. SCYNEXIS has a consensus price target of $24.00, suggesting a potential upside of 476.09%. Given SCYNEXIS's higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SCYNEXIS has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
SCYNEXIS	$20.60M	2.01	-$8.61M	-$3.84	N/A

Summary

Cognition Therapeutics and SCYNEXIS tied by winning 7 of the 14 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCYX vs. The Competition

Export

Metric	SCYNEXIS	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.30M	$3.04B	$6.76B	$12.51B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-1.08	19.59	25.78	24.73
Price / Sales	2.01	361.90	548.02	103.35
Price / Cash	N/A	56.85	29.14	36.96
Price / Book	0.46	4.27	10.84	6.52
Net Income	-$8.61M	$64.45M	$3.57B	$336.86M
7 Day Performance	9.06%	3.08%	2.43%	1.31%
1 Month Performance	490.92%	3.79%	0.76%	0.36%
1 Year Performance	-22.83%	34.58%	36.68%	30.89%

SCYNEXIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCYX SCYNEXIS	3.3415 of 5 stars	$4.07 +5.0%	$24.00 +490.4%	-30.0%	$40.51M	$20.60M	N/A	60	News Coverage
ASRT Assertio	2.3859 of 5 stars	$23.50 flat	$22.65 -3.6%	N/A	$151.81M	$118.71M	N/A	20	News Coverage Short Interest Decrease
SPRB Spruce Biosciences	2.8648 of 5 stars	$53.60 -2.0%	$163.00 +204.1%	+934.8%	$147.51M	N/A	N/A	20	News Coverage
TLSA Tiziana Life Sciences	0.5081 of 5 stars	$1.16 +0.4%	N/A	-23.1%	$146.98M	N/A	N/A	8
ADCT ADC Therapeutics	3.3181 of 5 stars	$1.16 +6.0%	$6.25 +441.1%	-61.4%	$146.90M	$81.36M	N/A	310	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCYX) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SCYNEXIS (SCYX) Competitors

SCYX vs. ASRT, SPRB, TLSA, ADCT, and CGTX

How does SCYNEXIS compare to Assertio?

Summary

How does SCYNEXIS compare to Spruce Biosciences?

Summary

How does SCYNEXIS compare to Tiziana Life Sciences?

Summary

How does SCYNEXIS compare to ADC Therapeutics?

Summary

How does SCYNEXIS compare to Cognition Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SCYNEXIS (SCYX) Competitors

SCYX vs. ASRT, SPRB, TLSA, ADCT, and CGTX

How does SCYNEXIS compare to Assertio?

Do analysts prefer ASRT or SCYX?

Do insiders & institutionals believe in ASRT or SCYX?

Does the media favor ASRT or SCYX?

Is ASRT or SCYX more profitable?

Which has preferable valuation and earnings, ASRT or SCYX?

Which has more risk & volatility, ASRT or SCYX?

Summary

How does SCYNEXIS compare to Spruce Biosciences?

Which has more risk & volatility, SCYX or SPRB?

Does the media refer more to SCYX or SPRB?

Is SCYX or SPRB more profitable?

Do insiders and institutionals believe in SCYX or SPRB?

Do analysts recommend SCYX or SPRB?

Which has stronger earnings and valuation, SCYX or SPRB?

Summary

How does SCYNEXIS compare to Tiziana Life Sciences?

Is SCYX or TLSA more profitable?

Do insiders and institutionals hold more shares of SCYX or TLSA?

Which has better earnings & valuation, SCYX or TLSA?

Does the media favor SCYX or TLSA?

Do analysts rate SCYX or TLSA?

Which has more risk and volatility, SCYX or TLSA?

Summary

How does SCYNEXIS compare to ADC Therapeutics?

Do analysts rate SCYX or ADCT?

Does the media favor SCYX or ADCT?

Do institutionals & insiders believe in SCYX or ADCT?

Which has more volatility and risk, SCYX or ADCT?

Is SCYX or ADCT more profitable?

Which has higher valuation and earnings, SCYX or ADCT?

Summary

How does SCYNEXIS compare to Cognition Therapeutics?

Do insiders & institutionals hold more shares of CGTX or SCYX?

Does the media refer more to CGTX or SCYX?

Which has more volatility and risk, CGTX or SCYX?

Is CGTX or SCYX more profitable?

Do analysts recommend CGTX or SCYX?

Which has higher valuation and earnings, CGTX or SCYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools